{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:46:25Z","timestamp":1774644385918,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"am","delay-in-days":301,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R33DA045851"],"award-info":[{"award-number":["R33DA045851"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA035772"],"award-info":[{"award-number":["P30DA035772"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.josat.2024.209544","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T14:21:06Z","timestamp":1729434066000},"page":"209544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort"],"prefix":"10.1016","volume":"168","author":[{"given":"Sharon","family":"Reif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen T.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay M.","family":"Daily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary F.","family":"Brolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Panas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan C.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayna B.","family":"Mazel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Wicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209544_bb0005","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","volume":"10","author":"Amato","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2S","key":"10.1016\/j.josat.2024.209544_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","author":"American Society of Addiction Medicine","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209544_bb0015","author":"American Society of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2024.209544_bb0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/08897077.2021.1944957","article-title":"Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses","volume":"43","author":"Andraka-Christou","year":"2022","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.josat.2024.209544_bb0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jadohealth.2022.08.026","article-title":"Ambivalence and stigma beliefs about medication treatment among young adults with opioid use disorder: A qualitative exploration of young adults\u2019 perspectives","volume":"72","author":"Bagley","year":"2023","journal-title":"Journal of Adolescent Health"},{"key":"10.1016\/j.josat.2024.209544_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108446","article-title":"Buprenorphine utilization among all Washington State residents\u2019 based upon prescription monitoring program data\u2014Characteristics associated with two measures of retention and patterns of care over time","volume":"127","author":"Banta-Green","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0035","author":"Bouchery"},{"issue":"4","key":"10.1016\/j.josat.2024.209544_bb0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: Development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"Journal of Addiction Medicine"},{"issue":"12","key":"10.1016\/j.josat.2024.209544_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/add.15959","article-title":"Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: A retrospective cohort study","volume":"117","author":"Burns","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2024.209544_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108040","article-title":"Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment","volume":"115","author":"Busch","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0055","author":"Centers for Medicare and Medicaid Services"},{"key":"10.1016\/j.josat.2024.209544_bb0060","author":"CMS"},{"key":"10.1016\/j.josat.2024.209544_bb0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jsat.2017.02.011","article-title":"The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010\u20132015)","volume":"85","author":"Cousins","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2019.07.014","article-title":"Preliminary results of the evaluation of the California Hub and Spoke Program","volume":"108","author":"Darfler","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2024.209544_bb0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.josat.2024.209544_bb0080","author":"Delphin-Rittmon"},{"issue":"1","key":"10.1016\/j.josat.2024.209544_bb0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jama.2014.7523","article-title":"The intention-to-treat principle: How to assess the true effect of choosing a medical treatment","volume":"312","author":"Detry","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2024.209544_bb0090","article-title":"\u201cYou\u2019re not supposed to be on it forever\u201d: Medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids","volume":"16","author":"Dickson-Gomez","year":"2022","journal-title":"Substance Abuse: Research and Treatment"},{"issue":"2","key":"10.1016\/j.josat.2024.209544_bb0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2024.209544_bb0100","article-title":"The recommended minimum length of pharmacotherapy for opioid use disorder is actually more than a year, but more research is needed","author":"Duffy","year":"2023","journal-title":"Health Affairs Forefront"},{"issue":"2","key":"10.1016\/j.josat.2024.209544_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.josat.2024.209544_bb0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/ADM.0000000000000914","article-title":"Association of counseling and psychotherapy on retention in medication for addiction treatment within a large Medicaid population","volume":"16","author":"Eren","year":"2022","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2024.209544_bb0115","doi-asserted-by":"crossref","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"The American Journal of Medicine"},{"issue":"4","key":"10.1016\/j.josat.2024.209544_bb0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine\u2013naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.josat.2024.209544_bb0125","author":"Gerrity"},{"issue":"12","key":"10.1016\/j.josat.2024.209544_bb0130","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2022.3118","article-title":"Association between buprenorphine treatment gaps, opioid overdose, and health care spending in US medicare beneficiaries with opioid use disorder","volume":"79","author":"Gibbons","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209544_bb0135","article-title":"Impact of medication-based treatment on health care utilization among individuals with opioid use disorder","volume":"appi.ps.20220549","author":"Gopaldas","year":"2023","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.josat.2024.209544_bb0140","author":"Greener"},{"issue":"4","key":"10.1016\/j.josat.2024.209544_bb0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.0887-378X.2004.00325.x","article-title":"Diffusion of innovations in service organizations: Systematic review and recommendations","volume":"82","author":"Greenhalgh","year":"2004","journal-title":"The Milbank Quarterly"},{"issue":"3","key":"10.1016\/j.josat.2024.209544_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2229-3485.83221","article-title":"Intention-to-treat concept: A review","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspectives in Clinical Research"},{"issue":"1","key":"10.1016\/j.josat.2024.209544_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.focus.2022.100063","article-title":"Drug overdose deaths among non-Hispanic black men in the U.S.: Age-specific projections through 2025","volume":"2","author":"Harris","year":"2022","journal-title":"AJPM Focus"},{"issue":"7","key":"10.1016\/j.josat.2024.209544_bb0160","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.josat.2024.209544_bb0165","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s11135-017-0584-6","article-title":"Confounding and collinearity in regression analysis: A cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour","volume":"52","author":"Johnston","year":"2018","journal-title":"Quality & Quantity"},{"key":"10.1016\/j.josat.2024.209544_bb0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jsat.2019.08.016","article-title":"Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania","volume":"106","author":"Kawasaki","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019\u2033","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2024.209544_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.josat.2024.209544_bb0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.josat.2024.209544_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12913-017-2247-7","article-title":"The quality of Medicaid and Medicare data obtained from CMS and its contractors: Implications for pharmacoepidemiology","volume":"17","author":"Leonard","year":"2017","journal-title":"BMC Health Services Research"},{"issue":"10","key":"10.1016\/j.josat.2024.209544_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/add.12266","article-title":"Comparison of behavioral treatment conditions in buprenorphine maintenance","volume":"108","author":"Ling","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"issue":"7","key":"10.1016\/j.josat.2024.209544_bb0200","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1176\/appi.ps.201700363","article-title":"Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults","volume":"69","author":"Manhapra","year":"2018","journal-title":"Psychiatric Services (Washington, D.C.)"},{"key":"10.1016\/j.josat.2024.209544_bb0205","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jsat.2019.07.013","article-title":"Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact","volume":"108","author":"Miele","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0210","series-title":"Motivational interviewing: Helping people change, 3rd edition (pp. xii, 482)","author":"Miller","year":"2013"},{"issue":"3","key":"10.1016\/j.josat.2024.209544_bb0215","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MLR.0000000000001689","article-title":"Variation in initiation, engagement, and retention on medications for opioid use disorder based on health insurance plan design","volume":"60","author":"Morgan","year":"2022","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2024.209544_bb0220","series-title":"Medications for opioid use disorder save lives","first-page":"25310","author":"NASEM","year":"2019"},{"key":"10.1016\/j.josat.2024.209544_bb0225","author":"National Institute on Drug Abuse (NIDA)"},{"key":"10.1016\/j.josat.2024.209544_bb0230","author":"National Quality Forum"},{"key":"10.1016\/j.josat.2024.209544_bb0235","author":"National Uniform Claim Committee"},{"key":"10.1016\/j.josat.2024.209544_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209121","article-title":"Ambivalence and contingencies: A qualitative examination of peer recovery coaches\u2019 attitudes toward medications for opioid use disorder","volume":"155","author":"Pasman","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"issue":"6","key":"10.1016\/j.josat.2024.209544_bb0245","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.josat.2024.209544_bb0250","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsat.2018.11.003","article-title":"Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system","volume":"97","author":"Rawson","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jsat.2019.07.007","article-title":"The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders","volume":"108","author":"Reif","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0260","author":"Robert Graham Center"},{"key":"10.1016\/j.josat.2024.209544_bb0265","author":"SAMHSA"},{"key":"10.1016\/j.josat.2024.209544_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108774","article-title":"Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes","volume":"139","author":"Samples","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0275","author":"SAS Institute Inc."},{"key":"10.1016\/j.josat.2024.209544_bb0280","author":"Single State View\u2014DQ Atlas"},{"key":"10.1016\/j.josat.2024.209544_bb0285","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.josat.2024.209544_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111125","article-title":"Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort","volume":"256","author":"Stewart","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2024.209544_bb0295","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.josat.2024.209544_bb0300","author":"U.S. Department of Agriculture, Economic Research Service"},{"issue":"2","key":"10.1016\/j.josat.2024.209544_bb0305","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209544_bb0310","author":"Washington State Department of Health"},{"key":"10.1016\/j.josat.2024.209544_bb0315","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jsat.2019.05.005","article-title":"West Virginia\u2019s model of buprenorphine expansion: Preliminary results","volume":"108","author":"Winstanley","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209544_bb0320","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States","volume":"169","author":"Wu","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209544_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108686","article-title":"Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data","volume":"136","author":"Zhang","year":"2022","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294987592400256X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294987592400256X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T06:19:11Z","timestamp":1733293151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294987592400256X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":65,"alternative-id":["S294987592400256X"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209544","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209544"}}